Featured
Health Topics
Any CategoryDiseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Carcinoma
Search Clinical Trials
Active, Not Recruiting
Meclizine for Hepatocellular Carcinoma (External Link)
The constitutive androstane receptor (CAR, NR1I3) is a nuclear receptor that plays a central role in hepatic detoxification of potentially toxic compounds, or xenobiotics. Chronic CAR activation by specific agonists …
Recruiting
Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma (External Link)
Primary outcomes: - the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRME with directed biopsy - compared to standard white-light endoscopy with 4-quadrant random …
Baylor Role:
Collaborator
Terminated
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal (External Link)
Everolimus has significantly improved outcomes following prior therapy. This study is a biomarker driven Phase II trial that will assess the activity of everolimus as first-line therapy for renal cell …
Terminated
Genetic Susceptibility to Kidney Cancer (External Link)
This study will further the understanding of the genetic events leading to the development of RCC; explore the genetic basis for genetic instability and how it affects cancer risk; and …
Baylor Role:
Lead Sponsor
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation (External Link)
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role:
Lead Sponsor